Uppsala, Sweden, July 4, 2013.  Orexo Labs  announced it has received approval from the F.D.A. for Zubsolv™ (buprenorphine/naloxone) sublingual tablet CIII.  Zubsolv is formulated for treatment for people suffering from opioid dependence

Advertisements